Literature DB >> 20202717

Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill.

R J Pugh1, R P D Cooke, G Dempsey.   

Abstract

Hospital-acquired pneumonia (HAP) is a common cause of morbidity and mortality in the critically ill, yet the optimal duration of antibiotic therapy is unknown. Too short a course may lead to treatment failure, whereas too long a course may lead to increased antibiotic resistance, antibiotic-related morbidity and increased costs. Standard duration of antibiotic therapy for Gram-negative (GN-)HAP at our institution is 5 days, significantly shorter than advocated in many current guidelines. We performed a retrospective review of all cases of GN-HAP on our critical care unit fulfilling clinical and microbiological criteria to investigate recurrence rate and mortality following short course antibiotic therapy. Seventy-nine eligible patients with GN-HAP were identified. Of these, 79% were receiving mechanical respiratory support at diagnosis; 42% had GN-HAP due to non-fermenting Gram-negative bacilli (NF-GNB) and 72% were treated with the recommended 5 day course of antibiotics. Two patients had clear evidence of non-resolution of pneumonia after 5 days of therapy. Overall recurrence rate was 14%, with relapse rates significantly higher among patients with NF-GNB when compared to patients with other Gram-negative organisms (17% vs 2%; P=0.03). The overall recurrence rate was no higher than rates reported in earlier studies (17-41%). Critical care mortality (34.2%) was also not in excess of previously reported values (18-57%). In this limited study, use of a 5 day course of appropriate antibiotics for GN-HAP does not appear to increase risk of recurrence or mortality when pneumonia resolution has been achieved prior to the cessation of therapy. Copyright (c) 2009 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202717     DOI: 10.1016/j.jhin.2009.10.009

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Assessment of the intensive care unit treatment of pneumonia at a veterans affairs facility.

Authors:  Carrie L Griffiths; Steven Pass; W Claibe Yarbrough
Journal:  Hosp Pharm       Date:  2014-11

3.  Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection.

Authors:  Phunsup Wongsurakiat; Sirapat Tulatamakit
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

4.  Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment.

Authors:  Gilles Capellier; Hélène Mockly; Claire Charpentier; Djillali Annane; Gilles Blasco; Thibault Desmettre; Antoine Roch; Christophe Faisy; Joel Cousson; Samuel Limat; Mariette Mercier; Laurent Papazian
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.